Alliance growth continues with debut of a new testing lab in Australia

Preview

来源: FierceBiotech

U.K.-based CRO Alliance Pharma continues to expand with the opening of a 20,000-square-foot facility in Australia that will provide small and large molecule bioanalytical testing.

Alliance Pharma continued its expansion plans with the opening of a new bioanalytical lab in Brisbane, Australia, to support preclinical and clinical testing.

The 20,000-square-foot facility will provide small- and large-molecule bioanalytical services for a region with limited choices for bioanalytical support, the company said in a Dec. 7 press release.

“It will allow biotech companies to work with us in Australia in the early phase and then transfer the knowledge on these assays to other regions to support the later development phases,” Jason (Hao) Wang, Alliance’s site president, Australia, said in the release. “Our objective is to accelerate the growth of our best-in-class portfolio and deliver industry-leading drug development service for our worldwide clients."

The U.K.-based CRO has been on a growth spurt this year. In late September, the company announced four additions to its C-suite to help bolster its growth.

That move followed Alliance’s acquisition in July of U.K.-based CRO Drug Development Solutions for an undisclosed sum.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。